Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities

Manufacturing results covered 100-gram scale, while initial biological findings came from human liver-cell laboratory models.

Rhea-AI Summary

Codexis (CDXS) presented new ECO Synthesis manufacturing and biological data at TIDES Europe, including product quality above 90%.

At 100-gram scale, the platform nearly halved cycle time, with performance maintained across three orders of magnitude in scale. New capabilities included incorporating tissue-targeting components into siRNA, a type of RNA therapeutic. An initial readout from an ongoing study of molecular structure and biological activity showed a 3- to 4-fold increase in potency in human liver-cell laboratory models versus identical siRNA made using traditional chemical methods. The material had defined phosphorothioate stereochemistry, or controlled spatial arrangements at specific chemical linkages. Codexis views the results as progress toward adoption readiness.

Positive

• Minor pointProduct quality above 90% was achieved at 100-gram manufacturing scale.
• Minor pointCycle time nearly halved, with manufacturing performance maintained across three orders of magnitude in scale.
• Minor pointInitial biological results showed 3- to 4-fold higher potency versus identical chemically synthesized siRNA in human liver-cell laboratory models.

Negative

• None.

Key Figures

Manufacturing scale: 100 grams Product quality: Above 90% Cycle time: Nearly halved +2 more

Manufacturing scale

100 grams

Scale at which product quality and manufacturing performance were demonstrated

Product quality

Above 90%

Achieved at 100-gram scale

Cycle time

Nearly halved

Manufacturing efficiency at 100-gram scale

Scale consistency

Three orders of magnitude

Performance maintained across this scale range

Potency increase

3- to 4-fold

Human hepatocyte in vitro models versus the identical siRNA made with traditional chemical methods

Key Terms

sirna, structure-activity relationship, phosphorothioate stereochemistry, in vitro

4 terms

sirna medical

"new data at TIDES Europe 2026 demonstrating the quality, stereo-control and manufacturing performance"

Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.

structure-activity relationship technical

"an ongoing structure-activity relationship (SAR) study"

A structure-activity relationship (SAR) is the systematic study of how small changes to a molecule’s shape or chemical features alter its effect on a biological target. Think of it like tuning the knobs on a gadget or changing teeth on a key to fit a lock better: SAR helps researchers make a compound more potent, safer, or longer-lasting. For investors, SAR work signals how readily a candidate can be improved, the likely time and cost to reach milestones, and the strength of patentable advantages.

phosphorothioate stereochemistry technical

"siRNA therapeutics with defined phosphorothioate stereochemistry"

Phosphorothioate stereochemistry describes the three-dimensional arrangement at a modified link in synthetic DNA/RNA drugs where one oxygen is swapped for sulfur, producing mirror-image forms like left- and right-hand versions of a glove. Those mirror-image forms can alter a drug’s stability, activity and side-effect profile and complicate manufacturing and quality control, so they affect development risk, regulatory review, production cost and commercial reliability for investors.

in vitro medical

"human hepatocyte in vitro models"

In vitro describes laboratory tests performed on cells, tissues, or biological molecules outside a living body—literally “in glass,” such as in test tubes or dishes. For investors, in vitro results are an early sign that a drug or technology has a desired effect under controlled conditions, but they don’t guarantee it will work or be safe in animals or people; think of them as a prototype tested on a bench rather than in real-world use.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Data shared at TIDES Europe demonstrates consistent and robust platform performance while delivering high product quality at scale, alongside new platform capabilities in targeting functionality and initial results showcasing that stereochemical control relates to biological efficacy

REDWOOD CITY, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, presented new data at TIDES Europe 2026 demonstrating the quality, stereo-control and manufacturing performance of its ECO Synthesis® Manufacturing Platform. The data included product quality and manufacturing control at 100-gram scale, improved process performance and initial biological evidence supporting the potential value of defined siRNA stereochemistry.

Codexis presented data demonstrating significant gains in manufacturing efficiency at the 100-gram scale, achieving product quality above 90% while nearly halving cycle time. Importantly, this performance was maintained consistently across three orders of magnitude in scale.

“As enzymatic RNA manufacturing advances, the important question is not simply whether it can scale, but how it performs at scale,” said Alison Moore, President and CEO of Codexis. “The data presented demonstrate the quality and manufacturing performance of ECO Synthesis at 100-gram scale, while continued process improvements are increasing productivity as we advance the platform toward industrialization.”

Building on this manufacturing performance, Codexis also presented new ECO Synthesis capabilities that align with optimal siRNA design and manufacturing, including efficient incorporation of tissue-targeting moieties, a key feature of today’s siRNA therapeutics.

Providing an initial readout from an ongoing structure-activity relationship (SAR) study, Codexis also shared biological data for siRNA therapeutics with defined phosphorothioate stereochemistry. Material produced using the scalable ECO Synthesis platform demonstrated a 3- to 4-fold increase in potency in human hepatocyte in vitro models compared with the identical siRNA synthesized using traditional chemical methods.

“Scale and quality provide the foundation, but the broader opportunity with enzymatic synthesis lies in the molecular precision it can enable,” said Stefan Lutz, Ph.D., Chief Scientific Officer of Codexis. “The ability to incorporate targeting functionality and control phosphorothioate stereochemistry gives us additional tools to explore how manufacturing can contribute to the design and performance of next-generation RNA therapeutics.”

Together, the data presented at TIDES Europe demonstrate continued progress toward adoption readiness for ECO Synthesis as a manufacturing platform for siRNA therapeutics. Quality and consistency at 100-gram scale, improving process productivity, expanded capabilities for targeted delivery and stereochemical control demonstrate the platform’s growing potential for scalable, differentiated RNA manufacturing.

About Codexis, Inc.

Codexis^® is a leading provider of high-performance enzymatic solutions for efficient and scalable therapeutics manufacturing. The Company is currently developing its proprietary ECO Synthesis® Manufacturing Platform, an aqueous enzymatic process that may offer a scalable alternative to traditional solid phase organic synthesis of oligonucleotide manufacturing. Initially, Codexis is applying its technology to address the rapidly growing demand for RNAi therapeutics. Codexis’ unique enzymes can drive improvements such as higher yields, increased purity, reduced energy usage and waste generation, stereoisomer control of siRNA, and improved overall capacity in manufacturing at substantially lower capital requirements, all of which may lead to greater efficiency and reduced costs. In addition, the Company supplies high-performance enzymes through its BioCatalysis business that are used in the manufacture of multiple commercially available small molecule therapeutics. For additional information, please visit https://www.codexis.com.

Codexis, Inc.
200 Penobscot Drive
Redwood City, CA 94063
+1 (650) 421-8100
codexis.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What manufacturing results did Codexis report for ECO Synthesis?

ECO Synthesis achieved product quality above 90% at 100-gram scale while nearly halving cycle time. Manufacturing performance was maintained consistently across three orders of magnitude in scale.

What did Codexis report about ECO Synthesis siRNA potency?

An initial readout from an ongoing structure-activity study showed a 3- to 4-fold increase in potency in human liver-cell laboratory models compared with identical siRNA synthesized using traditional chemical methods. The ECO Synthesis material had defined phosphorothioate stereochemistry, meaning controlled spatial arrangements at specific chemical linkages.